Novel therapy VNPP433-3Beta for all stages of prostate cancer
Official title: Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer
Funded at Isoprene Pharmaceuticals, INC. · NIH-11345297 · Data updated 2026-11-12
A new, oral drug candidate called VNPP433-3β is being developed to slow or stop prostate cancer from growing and spreading across all stages of the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Isoprene Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | June 4, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,022,522 |
| NIH project number | 5R44CA291285-02 |
| Project ID | NIH-11345297 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with various stages of prostate cancer who are candidates for systemic therapy and could benefit from treatments targeting AR signaling and related pathways.
✕Less likely to help
Patients whose cancer does not rely on the targeted pathways or who cannot tolerate this class of drugs may not benefit.
What this research studies
This project focuses on a targeted therapy that acts on multiple cancer-driving pathways to block tumor growth and metastasis in prostate cancer. The team has shown that VNPP433-3β and related compounds can degrade key cancer drivers, potentially offering superior activity compared with current treatments. The work includes preclinical testing to confirm safety, solubility, and effectiveness in lab models and animal models, with the aim of moving promising results toward human trials. If successful, this could lead to a new, more effective option for patients with different stages of prostate cancer.
Why it matters
Potential benefit: If successful, patients could gain a new oral therapy that halts tumor growth and spread, potentially improving survival and quality of life.
How similar studies have gone: Earlier similar compounds showed enhanced potency and favorable comparisons to existing therapies in preclinical models, supporting further development in humans.
Where this research is happening
-
Isoprene Pharmaceuticals, INC.
Baltimore, United States Active
Researchers
- Principal investigator: Ramamurthy, Vidya P — Isoprene Pharmaceuticals, INC.
- Study coordinator: Ramamurthy, Vidya P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.